Mouse Regenerating Myofibers Detected as False-Positive Donor Myofibers with Anti-Human Spectrin by Rozkalne, A et al.
Mouse Regenerating Myofibers Detected as False-Positive
Donor Myofibers with Anti-Human Spectrin
Anete Rozkalne,1 Carl Adkin,2 Jinhong Meng,2 Ariya Lapan,1 Jennifer E. Morgan,2 and Emanuela Gussoni1
Abstract
Stem cell transplantation is being tested as a potential therapy for a number of diseases. Stem cells isolated
directly from tissue specimens or generated via reprogramming of differentiated cells require rigorous testing for
both safety and efficacy in preclinical models. The availability of mice with immune-deficient background that
carry additional mutations in specific genes facilitates testing the efficacy of cell transplantation in disease
models. The muscular dystrophies are a heterogeneous group of disorders, of which Duchenne muscular dys-
trophy is the most severe and common type. Cell-based therapy for muscular dystrophy has been under
investigation for several decades, with a wide selection of cell types being studied, including tissue-specific stem
cells and reprogrammed stem cells. Several immune-deficient mouse models of muscular dystrophy have been
generated, in which human cells obtained from various sources are injected to assess their preclinical potential.
After transplantation, the presence of engrafted human cells is detected via immunofluorescence staining, using
antibodies that recognize human, but not mouse, proteins. Here we show that one antibody specific to human
spectrin, which is commonly used to evaluate the efficacy of transplanted human cells in mouse muscle, detects
myofibers in muscles of NOD/Rag1nullmdx5cv, NOD/LtSz-scid IL2Rcnull mice, or mdx nude mice, irrespective of
whether they were injected with human cells. These ‘‘reactive’’ clusters are regenerating myofibers, which are
normally present in dystrophic tissue and the spectrin antibody is likely recognizing utrophin, which con-
tains spectrin-like repeats. Therefore, caution should be used in interpreting data based on detection of single
human-specific proteins, and evaluation of human stem cell engraftment should be performed using multiple
human-specific labeling strategies.
Introduction
Stem cells of human origin are considered of potentialtherapeutic value for a number of diseases. Stem cells di-
rectly isolated from either discarded or consented human tissue
specimens, or generated via reprogramming of adult cells, re-
quire rigorous testing in preclinical models for both safety and
efficacy. Preclinical testing is facilitated by the availability of
immune-deficient murine models, such as nude (Flanagan,
1966; Pantelouris, 1968), NOD/Rag1null (Shultz et al., 2000), or
NSG (NOD/LtSz-scid IL2Rcnull or NOD scid gamma) mice
(Shultz et al., 2005, 2007). These immune-deficient mice are of-
ten crossed to immune-competent models that carry additional
genetic mutations in specific genes. After several backcrosses
into the immune-deficient background, immune-deficient
models for a specific disease are generated and they are suitable
for testing the safety and efficacy of stem cell transplantation.
The muscular dystrophies are a heterogeneous group of
disorders, one of which, Duchenne muscular dystrophy
(DMD), arises from primary mutations in the dystrophin
gene (Monaco et al., 1986; Hoffman et al., 1987). Cell-based
therapy for DMD has been under investigation for several
decades (Partridge et al., 1989; Karpati, 1990; Gussoni et al.,
1992; Huard et al., 1992; Karpati et al., 1993; Mendell et al.,
1995; Morandi et al., 1995; Neumeyer et al., 1998). Although
injection of expanded donor muscle cells into human muscle
is safe, the overall efficacy has been low, partially because of
cell death immediately after injection and host immune re-
action to the donor cells (Huard et al., 1994; Gussoni et al.,
1997; Beauchamp et al., 1999). Several additional cell types
are currently being studied for cell-based therapy of mus-
cular dystrophy, including mesenchymal stem cells (MSCs),
mesoangioblasts/pericytes, CD133 + cells, induced pluripo-
tent stem cells (iPSCs), and embryonic stem cells (ESCs)
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(Torrente et al., 2004; Dellavalle et al., 2007; Crisan et al., 2008;
Negroni et al., 2009; Darabi et al., 2012; Goudenege et al.,
2012; Tedesco et al., 2012). Human cells are routinely injected
into immune-deficient mouse models of muscular dystro-
phy, such as the mdx4cv and mdx5cv models bred into the
NSG or NOD/Rag1null background (Darabi et al., 2012;
Goudenege et al., 2012; Lapan et al., 2012); or into immune-
deficient mice in which the recipient muscle has been dam-
aged with cardiotoxin or by cryoinjury before injection
(Cooper et al., 2001, 2003; Brimah et al., 2004; Ehrhardt et al.,
2007; Crisan et al., 2008; Negroni et al., 2009; Meng et al., 2010,
2011). After transplantation, the presence of engrafted hu-
man cells is detected via immunofluorescence staining using
antibodies that recognize human, but not mouse, proteins.
One antibody in particular, anti-human spectrin (SPEC1),
has been used extensively to track the expression of human-
derived protein after injection of human cells into the muscle
of immune-deficient mice (Zheng et al., 2007; Crisan et al.,
2008; Goudenege et al., 2012). In the present study, we tested
the specificity with which individual antibodies that recog-
nize proteins of human, not mouse, origin track the presence
of transplanted human cells. Three immune-deficient mouse
models were analyzed: NOD/Rag1nullmdx5cv and mdx/nude,
which carry a mutation in the dystrophin gene (Partridge
et al., 1989; Boldrin et al., 2012; Lapan et al., 2012); and the
NSG immune-deficient model (Shultz et al., 2005, 2007),
where the muscle was preinjured with cardiotoxin or by
cryoinjury or irradiation followed by cryoinjury. It was
found that detection of engrafted human cells, using anti-
human-specific spectrin, results in visualization of false-
positive myofibers in all three murine models. In particular,
human spectrin-reactive myofibers were seen in animals that
had never been injected with human cells, and this occurred
after analyses of mice from all three immune-deficient
background strains. The reactivity was seen irrespective of
the type of fixation method used and it was specific to re-
generating myofibers, as demonstrated by coexpression in
these myofibers of embryonic myosin heavy chain (eMHC).
Utrophin was identified as the candidate protein that might
cross-react with the anti-human spectrin antibody, based on
its subsarcolemmal position, upregulation in regenerating
fibers (Gramolini et al., 1999), and the presence of a number
of spectrin-like repeat domains. Therefore, to circumvent
possible misinterpretation of transplant efficacy, detection of
engrafted human stem cells in mouse dystrophic or injured
muscle should be performed using multiple human-specific
antigen labeling strategies, either on the same or on consec-
utive tissue sections.
Materials and Methods
Mouse strains and care
Recipient NOD/Rag1nullmdx5cv mice were generated by
breeding the mdx5cv mutation into mice with a NOD/Rag1null
background for more than 10 generations (Lapan et al., 2012).
Homozygote females and hemizygote males were bred, and
100% of the progeny were used in cell transplantation
studies as described. NSG mice were purchased from the
Jackson Laboratory (Bar Harbor, ME) and were also kindly
donated by C. Kim (Boston Children’s Hospital, Boston,
MA). Dystrophin/utrophin double-null muscle tissue was
kindly provided by the laboratory of L.M. Kunkel (Boston
Children’s Hospital). mdx nude mice were generated as
previously described (Partridge et al., 1989). All procedures
involving live animals were approved by the Boston Chil-
dren’s Hospital Institutional Animal Care and Use Com-
mittee (IACUC) or under U.K. Home Office license, in
accordance with the Animals (Scientific Procedures) Act
1986.
Cell injections in recipient mice
For intramuscular injection of human fetal muscle cells,
1 · 105 human melanoma cell adhesion molecule (MCAM) +
cells were delivered to one tibialis anterior muscle of NOD/
Rag1nullmdx5cv mice, as previously described (Lapan et al.,
2012). Human fetal muscle cells were extracted from dis-
carded, deidentified tissue according to a protocol approved
by the Boston Children’s Hospital Committee on Clinical
Investigation and Internal Review Board. Inert green fluo-
rescent beads (diluted 1:10,000; Life Technologies, Carlsbad,
CA) were coinjected with the human cells to track the in-
jection site after sectioning. Transplanted muscles and non-
transplanted contralateral muscles were collected 1–2
months after transplantation and frozen in liquid nitrogen-
cooled isopentane. For NSG mice, the tibialis anterior muscle
was injured with 15ll of cardiotoxin as previously described
(Rivier et al., 2004). Regenerating muscles were collected 7
days after cardiotoxin injury.
For intramuscular injection of postnatal myoblasts, host
mice were mdx nude mice, aged 4 weeks. Tibialis anterior
muscles were cryoinjured, or irradiated with 18Gy 3 days
before cryoinjury and grafting as described previously (Bri-
mah et al., 2004; Boldrin et al., 2012). Into some of these
cryoinjured host muscles, either 1 · 106 donor human myo-
blasts, derived from a 2-year-old male patient with DMD, or
5 · 105 human skeletal muscle-derived CD133 + cells derived
from the paraspinal muscle of a 16-year-old male with ado-
lescent idiopathic scoliosis, or no cells, were grafted. Other
muscles were noninjured and nongrafted. Human cells were
supplied by the MRC CNMD Biobank London (REC refer-
ence number 06/Q0406/33). For all samples collected by the
Biobank after January 9, 2006, broad written consent for re-
search has been supplied by all patients or their parent/
guardian. All samples have been supplied anonymously to
the project. Copies of the consent forms are kept with the
Biobank in a locked cabinet and are also available in the
patient’s hospital notes at Great Ormond Street Hospital for
Children (London, UK) and Hammersmith Hospital (Lon-
don, UK). Muscles were removed for analysis 4 weeks after
cell transplantation. Vetergesic (buprenorphine hydrochlo-
ride; Alstoe Animal Health, Sheriff Hutton, UK) was ad-
ministered as analgesic.
Immunofluorescence staining
For analysis of NOD/Rag1nullmdx5cv and NSG mice, con-
secutive skeletal muscle tissue sections (10lm) were col-
lected on Tissue Tack microscope slides (Polysciences,
Warrington, PA). Various methods of fixation were tested:
slides were fixed for 3min in 100% methanol at room tem-
perature; or fixed in 4% paraformaldehyde (PFA) in phos-
phate-buffered saline (PBS) for 15min at room temperature
followed by 3min of permeabilization with 0.5% Triton X-
100; or left to air dry for 30min. After fixation, sides were
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washed once in PBS and blocked in 10% fetal bovine serum
(FBS)–PBS–0.1% Triton X-100 for 30min at room tempera-
ture. Slides were stained with polyclonal rabbit anti-
dystrophin (CAP6-10, diluted 1:2000) (Lidov et al., 1990;
Byers et al., 1993), monoclonal anti-human dystrophin (clone
Dy10/12B2, diluted 1:20; Vector Laboratories, Burlingame,
CA), rabbit anti-human lamin A/C (2966-1, diluted 1:500,
Epitomics, Burlingame, CA), rabbit anti-laminin (L9393, di-
luted 1:500; Sigma-Aldrich, St. Louis, MO), monoclonal mouse
anti-human spectrin (NCL-SPEC-1, Leica Biosystems, Buffalo
Grove, IL, or clone RBC2/3D5, diluted 1:100; Vector Labora-
tories, Burlingame, CA), monoclonal anti-human fetal
embryonic myosin heavy chain (F1.652, diluted 1:100; Devel-
opmental Studies Hybridoma Bank [DSHB]) diluted in 10%
FBS–PBS–0.1% Triton X-100 overnight at 4C. For secondary
antibody staining, DyLight 488-conjugated donkey anti-rabbit
(diluted 1:1000, preadsorbed, minimal cross-reactivity with
other species; Jackson Immunoresearch, West Grove, PA) and
Alexa Fluor 568-conjugated donkey anti-mouse IgG (diluted
1:1000; Life Technologies) antibodies diluted in 1· PBS were
used. Sections were coverslipped, using VECTASHIELD
mounting medium with 4¢,6-diamidino-2-phenylindole
(DAPI; Vector Laboratories, Burlingame, CA). Images were
taken using a · 20 objective lens on a Nikon Eclipse
E1000 microscope fitted with a Hamamatsu ORCA-ER CCD
camera.
For analysis of mdx/utrophin double-null muscle, frozen
tissue sections were fixed for 3min in 100% methanol fol-
lowed by three washes with 1 · PBS and 1hr of blocking
with 10% FBS and 0.1% Triton X-100, all at room tempera-
ture. Tissue sections were further stained according to the
procedure described in the M.O.M. (mouse on mouse) kit
protocol (BMK-2202; Vector Laboratories, Burlingame, CA).
Anti-human spectrin (Vector Laboratories, Burlingame, CA)
was diluted 1:100, anti-laminin (Sigma-Aldrich) was diluted
1:500, and anti-embryonic myosin heavy chain (DSHB) was
diluted 1:100. The primary mouse antibody was visualized
with fluorescein-conjugated streptavidin (SA-5001; Vector
Laboratories, Burlingame, CA) diluted 1:50 and with Alexa
Fluor 568-conjugated goat anti-rabbit (Life Technologies)
diluted 1:500.
For analysis of mdx nude mice, muscles were frozen in
isopentane chilled in liquid nitrogen and 7-lm cryosections
were cut throughout the muscles. Sections were rehydrated
in PBS for 5min, and then incubated in M.O.M. blocking
reagent (Vector Laboratories, Peterborough, UK) diluted in
10% normal goat serum (Vector Laboratories, Peterborough,
UK) in PBS for 1 hr at room temperature, according to the
manufacturer’s instructions. Sections were then stained with
primary antibodies to human spectrin (mouse monoclonal,
diluted 1:20; Vector Laboratories, Peterborough, UK), human
lamin A/C (mouse monoclonal, diluted 1:100; Vector La-
boratories, Peterborough, UK), neonatal myosin (mouse
monoclonal, diluted 1:50, BF34; Borrione et al., 1989), human
dystrophin (Mandys 106, diluted 1:100; MDA Monoclonal
Antibody Resource, Oswestry, UK), human neonatal myosin
(mouse monoclonal, diluted 1:100; Vector Laboratories, Pe-
terborough, UK), or utrophin (mouse monoclonal, diluted
1:50, Vector Laboratories, Peterborough, UK). All antibodies
were diluted in 10% normal goat serum and used alone or in
combination. Primary antibody incubation was for 1 hr at
room temperature or 4C overnight. Sections were washed in
PBS before incubation with secondary antibodies, Alexa
Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor
594-conjugated goat anti-rabbit IgG were both diluted 1:500
in PBS (Life Technologies) at room temperature for 1 hr.
Sections were again washed with PBS and mounted in
Fluoromount (Dako, Ely, UK) containing 4¢,6-diamidino-2-
phenylindole (DAPI, 100 ng/ml; Sigma-Aldrich). Sections
were visualized with epifluorescence, using a Leica DMR
microscope, and digitally captured with MetaMorph soft-
ware (Universal Imaging, Downington, PA).
Results and Discussion
Human fetal MCAM + muscle cells were isolated as pre-
viously described (Lapan and Gussoni, 2012; Lapan et al.,
2012). MCAM + cells were injected via the intramuscular
route into NOD/Rag1nullmdx5cv recipient mice and the
muscles were examined 1–2 months after injection. Im-
munostaining with mouse anti-human spectrin and rabbit
anti-dystrophin (this antibody recognizes both human and
mouse dystrophin) revealed the presence of myofibers pos-
itive for both proteins (Fig. 1A–C), which demonstrated that
human donor cells had fused to these myofibers. In different
sections, spectrin-reactive myofibers appeared to contain
human-derived nuclei based on the expression of human-
specific lamin A/C (Fig. 1D–F), confirming the presence of
injected human cells. In addition, clusters or individual human
spectrin-positive myofibers that were negative for dystrophin
expression were also seen (Fig. 1G–I and Supplementary
Fig. S1; supplementary data are available online at www
.liebertpub.com/hum). Given the low abundance of the dys-
trophin transcript and an estimated time of 16hr to transcribe
the entire molecule (Tennyson et al., 1995), we initially thought
that these human spectrin-reactive myofibers represented ex-
pression of successfully engrafted human cells that required
additional time to display dystrophin expression.
To further study the nature of these human spectrin-
reactive myofibers and determine whether this expression
unequivocally marks the engraftment of donor human cells,
tissue sections of 2- to 4-month-old NOD/Rag1nullmdx5cv
mice not injected with human cells were analyzed (Fig. 2).
Consecutive muscle tissue sections were stained with mouse
anti-human spectrin or with mouse anti-human dystrophin.
Human spectrin-reactive fibers were detected in mice that
had never been injected with human cells (Fig. 2A), whereas
dystrophin was never detected in the same fibers (Fig. 2B).
These human spectrin-reactive myofibers were detected ir-
respective of the fixation method used: methanol, PFA, or
unfixed tissue (Supplementary Fig. S2).
On the basis of the morphology, we suspected that these
could be clusters of regenerating myofibers, which are nor-
mally present in dystrophic tissue. To confirm this, consec-
utive tissue sections of NOD/Rag1nullmdx5cv mice were
costained with rabbit anti-laminin and mouse anti-embryonic
myosin heavy chain antibodies (Fig. 2D and E). Positive
staining for embryonic myosin heavy chain confirmed that
the human spectrin-reactive clusters contained regenerating
myofibers (Fig. 2E). To address whether other immune-
deficient mouse strains that are used for human cell trans-
plantation experiments exhibited similar findings, NSG mice
(Shultz et al., 2005, 2007) were injured with cardiotoxin in
one tibialis anterior muscle. The injured muscles, which were
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never injected with human cells, were collected 7 days after
injury. Immunostaining of muscle tissue sections with anti-
human spectrin again revealed reactivity of this antibody
with small clusters of myofibers (Fig. 2G); however, they did
not express human dystrophin (Fig. 2H). These myofibers
were within the cardiotoxin-injured area, as indicated by the
expression of eMHC (Fig. 2K). Thus, under all conditions
tested, regenerating human spectrin-reactive myofibers were
detected in mice that were never injected with human fetal
cells.
In mdx nude host mice, human postnatal myoblasts grafted
into cryoinjured host muscles were also able to contribute to
regenerated muscle fibers expressing human spectrin; many
of these fibers also contained a nucleus expressing human
lamin A/C 21 days after engraftment (Fig. 3A). As these
donor myoblasts were derived from a patient with DMD,
dystrophin could not be used as a marker of muscle of donor
origin. In a muscle that had not been injured or grafted with
human cells, clusters of small human spectrin-positive fibers
were detected (Fig. 3B); however, no human nuclei (expres-
sing human lamin A/C) were seen in or near these clusters.
It was therefore suspected, because of their small size and
central nuclei within the fibers, that these clusters were re-
generating mouse muscle fibers, and did not contain nuclei
of human origin. To confirm that these areas were in the
process of regeneration, serial sections were stained with an
antibody to neonatal myosin heavy chain, which is expressed
in recently regenerated muscle fibers (Gross and Morgan,
1999). The vast majority of the fibers reactive to the human
spectrin antibody were indeed regenerating myofibers as
confirmed by neonatal myosin staining (Fig. 3B and C). The
same myofibers were also reactive to the protein utrophin,
which is upregulated and expressed in a subsarcolemmal
position in regenerating fibers (Gramolini et al., 1999).
To investigate whether utrophin is the cause of this cross-
reaction of human specific-spectrin antibody with recently
regenerated mouse muscle fibers, a BLAST search was per-
formed to find conserved amino acid sequences between
human b-spectrin and mouse utrophin (Supplementary Fig.
S3). Mouse utrophin contains a number of spectrin-like re-
peat domains that allow its binding to actin (Rybakova and
Ervasti, 2005) (Supplementary Fig. S3). To confirm whether
upregulation of utrophin was responsible for the cross-
reaction of the human specific spectrin antibody with mouse
muscle fibers, transverse cryosections of mdx/utrophin
double-null tibialis anterior (TA) muscles were stained with
anti-eMHC and laminin to detect regenerating muscle fibers
and with human spectrin and laminin on consecutive sec-
tions (Fig. 4). In mdx/utrophin double-null tissue sections,
the human-specific spectrin antibody did not display
FIG. 1. Clusters of human spectrin-positive myofibers are detected in mice injected with human cells. (A–I) Recipient
NOD/Rag1nullmdx5cv muscles 45 days after injection of 1· 105 MCAM + human fetal cells. (A–C) Coexpression of human
spectrin and dystrophin (antibody recognizes both mouse and human proteins) documents human cell engraftment in
myofibers. (D–F) Human spectrin-positive myofibers contain nuclei expressing human-specific lamin A/C. (G–I) Clusters of
small myofibers reactive to human spectrin but negative for dystrophin expression. H-spectrin, human spectrin; h-lamin
A/C, human lamin A/C. Scale bar: 50lm
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reactivity to regenerating fibers, supporting the conclusion
that utrophin is the likely cross-reacting protein (Fig. 4).
On the basis of this evidence, in order to avoid incorrectly
identifying recently regenerated mouse muscle fibers as
muscle fibers of the donor, human origin, multiple markers
that detect the presence of engrafted human cells must be
used. When host mouse muscles are injected with donor cells
derived from an unaffected individual, costaining with
dystrophin can provide a second marker for donor muscle.
To distinguish between naturally occurring revertant fibers
that express dystrophin in mdxmice (Hoffman et al., 1990; Lu
et al., 2000; Yokota et al., 2006), a human-specific dystrophin
antibody may be used (Fig. 5). For DMD donor cells, how-
ever, the use of dystrophin as a second marker of muscle
fibers of donor origin is not possible. Therefore, if fibers are
small, centrally nucleated, are found in a tight cluster, and
have no human lamin A/C-positive nuclei, then they are
likely to be regenerating mouse fibers. Four weeks after
grafting, bona fide muscle fibers of human origin will be of
normal size, in diffuse clusters and either contain, or be in
close proximity, to human lamin A/C-positive nuclei (Fig. 5).
Stem cell transplantation is one of the strategies being
tested for the therapy of several human diseases, including
muscular dystrophy. In addition to the promise held by the
use of embryonic stem cells (ESCs), the field of cell-based
therapy has gained increased interest with the development
FIG. 2. Clusters of human spectrin-positive myofibers are detected in mice never injected with human cells; these are
regenerating myofibers. (A–C) NOD/Rag1nullmdx5cv muscle tissue sections from animals not injected with human cells.
Myofibers reactive to the human-spectrin antibody are detected. (D–F) The human spectrin-reactive myofibers are re-
generating myofibers. Consecutive sections stained for laminin and embryonic myosin heavy chain (eMHC) reveal the
identity of the spectrin-reactive myofibers in NOD/Rag1nullmdx5cv mice. (G–L) NSG mouse muscles from 6-month-old
animals never injected with human cells and injured with cardiotoxin show expression of human spectrin in regenerating
myofibers. (G–I) Human spectrin-positive myofibers are negative for dystrophin. ( J–L) In consecutive sections, the spectrin-
reactive myofibers are within the injured area, as documented by coexpression of laminin and eMHC. Scale bar: 50 lm.
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FIG. 3. Examples of ‘‘true’’ human spectrin-positive fibers (A) and ‘‘false’’ human spectrin-positive fibers (B) on mdx nude
muscle sections. Nuclei were counterstained with 4¢,6-diamidino-2-phenylindole (DAPI; blue). (A) Immunostaining of human
lamin A/C and human spectrin (both green) on a transverse cryosection of an mdx nude tibialis anterior (TA) muscle that had
been grafted with Duchenne muscular dystrophy (DMD) myoblasts 21 days earlier. Bona fide human spectrin-positive fibers
were confirmed by the presence of human lamin A/C-positive nuclei within the fibers. (B) Immunostaining of human lamin
A/C and human spectrin (both red) on a transverse cryosection from a noninjured, nongrafted mdx nude TA muscle. Fibers
expressing human spectrin-positive fibers are not of human origin, as they do not contain human lamin A/C-positive nuclei.
(C) Immunostaining of neonatal myosin heavy chain (nMHC; green) on a section serial to that shown in (B). The ‘‘false’’
human spectrin-reactive fibers are mostly regenerating muscle fibers, expressing nMHC. (D) Immunostaining of utrophin
(green) on a section serial to that shown in (B) and (C). The ‘‘false’’ human spectrin-reactive fibers were also utrophin-positive,
suggesting a cross-reaction of the human spectrin antibody with mouse utrophin. Scale bars: 25 lm.
FIG. 4. Human spectrin does not recognize regenerating myofibers in mdx/utrophin double-null mice. Transverse cryo-
sections of mdx/utrophin double-null mouse TA muscle. Sections were stained with antibodies to eMHC, laminin, and human
spectrin. A group of regenerating fibers expressing neonatal myosin is not recognized by antibodies to human spectrin,
confirming that utrophin is the likely cross-reactive protein. Scale bar: 50lm.
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of strategies that generate induced pluripotent stem cells
(iPSCs). iPSCs are derived from adult, committed cell types
and have the potential to be expanded in unlimited numbers,
making them attractive candidates for downstream transla-
tional applications. Preclinical testing of human-derived cells
in immune-deficient mouse models of specific diseases is
often the next step toward translation into the clinic. For
DMD, several immune-deficient animal models are available
that also carry a mutation in the dystrophin gene (Partridge
et al., 1989; Boldrin et al., 2012; Darabi et al., 2012; Lapan et al.,
2012). After transplantation of human cells, detection of en-
grafted myofibers expressing human proteins is necessary.
Some of the most commonly used antibodies are as follows:
anti-human dystrophin (Millipore, Bedford, MA) or Mandys
106 (G. Morris, MDA Monoclonal Antibody Resource); anti-
human spectrin (SPEC1); anti-human lamin A/C (Epi-
tomics); and anti-dystrophin (mouse and human). Although
the use of multiple human-specific markers to track the
presence of donor human cells seems standard practice,
several reports have relied, in at least part of their work, on
the detection of a single antigen, anti-human spectrin, to
detect the expression of a human-derived protein in myofi-
bers (Pye et al., 2004; Crisan et al., 2008; Goudenege et al.,
2012). We found that the use of this antibody alone to detect
the presence of engrafted human cells can give false positive
results. Our data demonstrate that the antibody reacts with
clusters of regenerating myofibers in dystrophic mice, even
when the animals were never injected with human cells.
Notably, these reactive myofibers were detected irrespective
of the fixation method used and in all mouse strains
tested, including NSG mice whose muscles were injured
with cardiotoxin.
Therefore, caution should be used in interpreting immuno-
fluorescence staining based on the detection of single human-
specific proteins, and the evaluation of human cell engraftment
using multiple human-specific antibodies is strongly re-
commended. One of the preferred combinations includes the
use of an anti-dystrophin antibody, either human specific or
that recognizes both mouse and human proteins, together with
anti-human lamin A/C. This will allow the codetection of
human-derived nuclei within the myofibers expressing dys-
trophin. Alternatively, the use of the human-specific spectrin
together with an anti-dystrophin or anti-human lamin A/C
antibody will also ensure coexpression of both proteins in the
same myofibers, which is indicative of human cell engraft-
ment. Conversely, the presence of human spectrin alone or in
combination with anti-lamin A/C does not necessarily mark
mouse myofibers engrafted with human cells. In fact, the
presence of human lamin A/C-expressing nuclei can be due to
individual cells residing near the plane of spectrin-reactive
myofibers, but not necessarily fused within a myofiber (Meng
et al., 2010). Thus, although there is considerable excitement
over the prospect of developing new cell-based strategies for
the therapy of many diseases, including muscular dystrophy,
caution should be taken in the design of the evaluation steps
and the possible limitations or pitfalls with specific assays.
FIG. 5. Human spectrin, human lamin A/C, and human dystrophin are coexpressed in myofibers of mdx nude mice 4
weeks after injection of human cells. (A and D) Immunostaining of human lamin A/C and human spectrin (both green); (B
and E) human neonatal myosin (red); and (C and F) human dystrophin (Mandys 106, green) on serial sections of mdx nude
muscles that had been cryoinjured and intramuscularly transplanted with human muscle-derived CD133+ cells 4 weeks
previously. Yellow arrowheads: a human spectrin-positive fiber containing a human lamin A/C nucleus, which is also
human dystrophin-positive, but neonatal myosin-negative; white arrows: a human spectrin-positive fiber containing a hu-
man lamin A/C nucleus, which is also human dystrophin-positive and human neonatal myosin-positive. Nuclei were
counterstained with DAPI (blue). Scale bars: top, 25lm; bottom, 10 lm.
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